CEP131

Across TCGA pan-cancer cohorts, CEP131 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CEP131 data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CEP131 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CEP131 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

LUAD, CCRCC, and PDAC are the cancer types where CEP131 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.995	0.485	.003	35	view →
CCRCC	OS	Median	All	0.647	1.000	.005	16	view →
PDAC	DFS	Quartile	II,III,IV	0.528	0.861	.008	13	view →
LSCC	OS	Median	All	1.000	0.793	.025	4	view →
GBM	OS	Quartile	All	0.753	0.883	.032	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CEP131–LUAD (DFS)

Open the LUAD breakdown →